A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib

BACKGROUND: Patients with glioblastoma (GBM) have a dramatically poor prognosis. The recent REGOMA trial suggested an overall survival (OS) benefit of regorafenib in recurrent GBM patients. Considering the extreme genetic heterogeneity of GBMs, we aimed to identify molecular biomarkers predictive of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Santangelo, Alessandra, Rossato, Marzia, Lombardi, Giuseppe, Benfatto, Salvatore, Lavezzari, Denise, De Salvo, Gian Luca, Indraccolo, Stefano, Dechecchi, Maria Cristina, Prandini, Paola, Gambari, Roberto, Scapoli, Chiara, Di Gennaro, Gianfranco, Caccese, Mario, Eoli, Marica, Rudà, Roberta, Brandes, Alba Ariela, Ibrahim, Toni, Rizzato, Simona, Lolli, Ivan, Lippi, Giuseppe, Delledonne, Massimo, Zagonel, Vittorina, Cabrini, Giulio
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Basic and Translational Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7906066/
https://ncbi.nlm.nih.gov/pubmed/32661549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa156
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky